Pediatric Gastroenterology, Hepatology & Nutrition

  • 제25권1호
  • /
  • Pages.1-12
  • /
  • 2022
  • /
  • 2234-8646(pISSN)
  • /
  • 2234-8840(eISSN)
대한소아소화기영양학회 (The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition)
권호 표지
DOI QR코드

DOI QR Code

Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis

  • Talebi, Saeedeh (Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences) ;
  • Day, Andrew S. (Department of Pediatrics, University of Otago (Christchurch)) ;
  • Rezaiyan, Majid Khadem (Department of Community Medicine, Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine, Mashhad University of Medical Sciences) ;
  • Ranjbar, Golnaz (Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences) ;
  • Zarei, Mitra (Department of Knowledge and Information Science, Faculty of Medicine, Mashhad University of Medical Sciences) ;
  • Safarian, Mahammad (Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences) ;
  • Kianifar, Hamid Reza (Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences)
  • 투고 : 2021.08.04
  • 심사 : 2022.01.07
  • 발행 : 2022.01.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Inflammation plays an important role in the outcome of patients with cystic fibrosis (CF). It may develop due to cystic fibrosis transmembrane conductance regulator protein dysfunction, pancreatic insufficiency, or prolonged pulmonary infection. Fecal calprotectin (FC) has been used as a noninvasive method to detect inflammation. Therefore, the aim of the current meta-analysis was to investigate the relationship between FC and phenotype severity in patients with CF. In this study, searches were conducted in PubMed, Science Direct, Scopus, and Embase databases up to August 2021 using terms such as "cystic fibrosis," "intestine," "calprotectin," and "inflammation." Only articles published in English and human studies were selected. The primary outcome was the level of FC in patients with CF. The secondary outcome was the relationship between FC and clinical severity. Statistical analysis was performed using Comprehensive Meta-Analysis software. Of the initial 303 references, only six articles met the inclusion criteria. The mean (95% confidence interval [CI]) level of FC was 256.5 mg/dL (114.1-398.9). FC levels were significantly associated with pancreatic insufficiency (mean, 243.02; 95% CI, 74.3 to 411.6; p=0.005; I2=0), pulmonary function (r=-0.39; 95% CI, -0.58 to -0.15; p=0.002; I2=60%), body mass index (r=-0.514; 95% CI, 0.26 to 0.69; p<0.001; I2=0%), and Pseudomonas colonization (mean, 174.77; 95% CI, 12.5 to 337.02; p=0.035; I2=71%). While FC is a reliable noninvasive marker for detecting gastrointestinal inflammation, it is also correlated with the severity of the disease in patients with CF.

키워드

참고문헌

  1. Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 2012;45:1132-44. https://doi.org/10.1016/j.clinbiochem.2012.05.034
  2. Roesch EA, Nichols DP, Chmiel JF. Inflammation in cystic fibrosis: an update. Pediatr Pulmonol 2018;53(S3):S30-50. https://doi.org/10.1002/ppul.24129
  3. Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros 2015;14:419-30. https://doi.org/10.1016/j.jcf.2015.03.003
  4. Belcher CN, Vij N. Protein processing and inflammatory signaling in cystic fibrosis: challenges and therapeutic strategies. Curr Mol Med 2010;10:82-94. https://doi.org/10.2174/156652410791065408
  5. Briars G. Intestinal inflammation in cystic fibrosis. Arch Dis Child 2001;84:374-5. https://doi.org/10.1136/adc.84.4.373c
  6. Mack DR, Flick JA, Durie PR, Rosenstein BJ, Ellis LE, Perman JA. Correlation of intestinal lactulose permeability with exocrine pancreatic dysfunction. J Pediatr 1992;120:696-701. https://doi.org/10.1016/s0022-3476(05)80230-6
  7. Taylor-Cousar JL, Von Kessel KA, Young R, Nichols DP. Potential of anti-inflammatory treatment for cystic fibrosis lung disease. J Inflamm Res 2010;3:61-74.
  8. Rumman N, Sultan M, El-Chammas K, Goh V, Salzman N, Quintero D, et al. Calprotectin in cystic fibrosis. BMC Pediatr 2014;14:133. https://doi.org/10.1186/1471-2431-14-133
  9. Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993;34:1357-63. https://doi.org/10.1136/gut.34.10.1357
  10. Parisi GF, Papale M, Rotolo N, Aloisio D, Tardino L, Scuderi MG, et al. Severe disease in Cystic Fibrosis and fecal calprotectin levels. Immunobiology 2017;222:582-6. https://doi.org/10.1016/j.imbio.2016.11.005
  11. Schnapp Z, Hartman C, Livnat G, Shteinberg M, Elenberg Y. Decreased fecal calprotectin levels in cystic fibrosis patients after antibiotic treatment for respiratory exacerbation. J Pediatr Gastroenterol Nutr 2019;68:282-4. https://doi.org/10.1097/MPG.0000000000002197
  12. Ellemunter H, Engelhardt A, Schuller K, Steinkamp G. Fecal calprotectin in cystic fibrosis and its relation to disease parameters: a longitudinal analysis for 12 years. J Pediatr Gastroenterol Nutr 2017;65:438-42. https://doi.org/10.1097/MPG.0000000000001544
  13. Fraser-Pitt D, O'Neil D. Cystic fibrosis - a multiorgan protein misfolding disease. Future Sci OA 2015;1:FSO57.
  14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Int J Surg 2010;8:336-41. https://doi.org/10.1016/j.ijsu.2010.02.007
  15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5. https://doi.org/10.1007/s10654-010-9491-z
  16. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.
  17. Melsen WG, Bootsma MC, Rovers MM, Bonten MJ. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect 2014;20:123-9. https://doi.org/10.1111/1469-0691.12494
  18. Adriaanse MP, van der Sande LJ, van den Neucker AM, Menheere PP, Dompeling E, Buurman WA, et al. Evidence for a cystic fibrosis enteropathy. PLoS One 2015;10:e0138062. https://doi.org/10.1371/journal.pone.0138062
  19. Dhaliwal J, Leach S, Katz T, Nahidi L, Pang T, Lee JM, et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2015;60:521-6. https://doi.org/10.1097/MPG.0000000000000683
  20. Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010;51:304-8. https://doi.org/10.1097/mpg.0b013e3181d1b013
  21. Stallings VA, Tindall AM, Mascarenhas MR, Maqbool A, Schall JI. Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: a randomized controlled trial. PLoS One 2020;15:e0232685. https://doi.org/10.1371/journal.pone.0232685
  22. de Freitas MB, Moreira EAM, Tomio C, Moreno YMF, Daltoe FP, Barbosa E, et al. Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis. PLoS One 2018;13:e0198457. https://doi.org/10.1371/journal.pone.0198457
  23. Garg M, Leach ST, Coffey MJ, Katz T, Strachan R, Pang T, et al. Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children. J Cyst Fibros 2017;16:631-6. https://doi.org/10.1016/j.jcf.2017.03.010
  24. Garg M, Leach ST, Pang T, Needham B, Coffey MJ, Katz T, et al. Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old. J Cyst Fibros 2018;17:109-13. https://doi.org/10.1016/j.jcf.2017.07.011
  25. Wiecek S, Wos H, Kordys-Darmolinska B, Sankiewicz-Szkolka M, Grzybowska-Chlebowczyk U. The concentration of calprotectin in the stools of children with diagnosed cystic fibrosis. Prz Gastroenterol 2017;12:38-43. https://doi.org/10.1007/s11377-016-0127-z
  26. Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine. J Cyst Fibros 2017;16 Suppl 2:S14-23. https://doi.org/10.1016/j.jcf.2017.07.014
  27. Marsland BJ, Gollwitzer ES. Host-microorganism interactions in lung diseases. Nat Rev Immunol 2014;14:827-35. https://doi.org/10.1038/nri3769
  28. Hoen AG, Li J, Moulton LA, O'Toole GA, Housman ML, Koestler DC, et al. Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis. J Pediatr 2015;167:138-47.e1-3. https://doi.org/10.1016/j.jpeds.2015.02.049
  29. Anderson JL, Miles C, Tierney AC. Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis: a systematic review. J Cyst Fibros 2017;16:186-97. https://doi.org/10.1016/j.jcf.2016.09.004
  30. Hery-Arnaud G, Boutin S, Cuthbertson L, Elborn SJ, Tunney MM. The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis? J Cyst Fibros 2019;18:13-21. https://doi.org/10.1016/j.jcf.2018.11.003
  31. Sabharwal S. Gastrointestinal manifestations of cystic fibrosis. Gastroenterol Hepatol (N Y) 2016;12:43-7.
  32. Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 2004;72:6040-9. https://doi.org/10.1128/IAI.72.10.6040-6049.2004
  33. Werlin S, Benuri-Silbiger I, Cohen L, Kerem E, Aviram M, Bentur L, et al. Enteropathy - a new finding in cystic fibrosis. J Cyst Fibros 2008;7 Suppl 2:S79.
  34. Bruzzese E, Callegari ML, Raia V, Viscovo S, Scotto R, Ferrari S, et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One 2014;9:e87796. https://doi.org/10.1371/journal.pone.0087796
  35. Coffey MJ, Nielsen S, Wemheuer B, Kaakoush NO, Garg M, Needham B, et al. Gut microbiota in children with cystic fibrosis: a taxonomic and functional dysbiosis. Sci Rep 2019;9:18593. https://doi.org/10.1038/s41598-019-55028-7